OSTEOGENESIS IMPERFECTA (OI)

Definition

  • Also referred to as “brittle bone disease.”
  • Rare hereditary connective tissue disorder (~1 case per 200,000 live births).
  • Marked variability in clinical presentation:
    • Moderate to severe forms often present in infancy (fractures with little/no trauma).
    • Mild forms may only appear later (adulthood) with premature osteoporosis.

Etiology & Genetic Background

  • ~90% of cases: Autosomal dominant germline mutations in type I collagen genesCOL1A1 and COL1A2.
    • Collagen type I is crucial for normal bones, sclerae, tendons, ligaments, teeth, and skin.
    • Disease can result from abnormal structure or reduced production of type I collagen.
  • Mutations in other collagen-related genes (e.g., encoding cartilage-associated proteins) found in a minority of OI patients.
  • Intra-familial variability: Patients with the same mutation may have different severities (involving other genetic or environmental factors).

Key Clinical Features

  • Recurrent bone fractures (often minimal or no trauma).
  • Blue sclerae (translucent sclera revealing underlying uveal tissue).
  • Opalescent teeth (dentinogenesis imperfecta) → teeth appear grayish or bluish, may be fragile.
  • Easy bruising of tissues.
  • Basilar skull deformities with possible neurological complications.
  • Hearing loss (due to fracture of ossicles or inner ear involvement).
  • Ligament laxity with hypermobility.

Clinical Subtypes

  1. Type I OI (Mild)
    • Typically mild manifestations:
      • Infrequent fractures (long bones, ribs).
      • Normal stature, possible premature osteoporosis.
      • Mild scoliosis can occur.
      • Blue sclerae.
      • Teeth: normal appearance or opalescent.
      • Early-onset hearing loss is common.
    • Often related to a COL1A1 allele deletion → normal collagen structure but reduced overall production.
  2. Type II OI (Lethal Perinatal)
    • Multiple severe fractures in utero or at birth.
    • Typically fatal shortly after delivery (respiratory failure).
  3. Types III, IV, V, VI, VII, and VIII
    • Severe bone fragility with frequent fractures and limb deformities.
    • Progressive skeletal deformities:
      • Bowed long bones, scoliosis, short stature.
      • Basilar skull changes → possible nerve compression.
      • Hearing loss if ossicles are affected.
    • Joint hypermobility can be present.
    • Type III: progressive deforming form leading to wheelchair use.
    • Type IV: somewhat less growth retardation vs. Type III; may have normal sclera.
    • Type V: “Congenital brittle bones with redundant callus;” no dentinogenesis imperfecta.
    • Type VI: “Congenital brittle bones with mineralization defect;” accumulation of osteoid in bone tissue.
    • Type VII: Rare, recessive, with rhizomelia (shortening near proximal limb segments).
    • Type VIII: Recessive, prolyl 3-hydroxylase 1 deficiency → severely undermineralized bone matrix.

Laboratory Findings

  • Calcium, phosphorus, PTH often normal in typical OI.
  • Hypercalciuria may occur, correlates with disease severity.
  • Bone markers:
    • Formation markers (bone-specific alkaline phosphatase, osteocalcin, collagen propeptides) may be low in severe disease (impaired osteoblast function).
    • Resorption markers (urinary hydroxyproline, N/C-telopeptide crosslinks) may be high, reflecting increased collagen breakdown.
  • Bone biopsy typically not necessary; if done, may show:
    • Disorganized bone architecture.
    • High turnover with decreased cortical width, trabecular number, and cancellous bone volume.

Differential Diagnosis

  • Rickets (various forms).
  • Child abuse (non-accidental fractures).
  • Idiopathic juvenile osteoporosis.
  • Hypophosphatasia (tissue-nonspecific alkaline phosphatase deficiency).
  • Juvenile Paget disease.
  • Fibrous dysplasia, Ehlers-Danlos syndrome, Menkes disease, Cole-Carpenter syndrome.

Diagnosis

  • Clinical diagnosis: Recurrent fractures, blue sclerae, family history, dentinogenesis imperfecta, hearing loss.
  • Genetic testing: Mutational analysis of COL1A1 and COL1A2.
  • Skeletal radiographs: May reveal osteopenia, thin cortices, multiple fractures in different healing stages.

Treatment & Management

  • Team approach: Genetics, orthopedics, neurology, physical/occupational therapy, dental, ENT, psychology, endocrinology.
  • Goals:
    • Reduce fracture frequency.
    • Maximize mobility and independence.
    • Prevent/managing deformities (e.g., scoliosis).
    • Control pain.
  • Monitoring:
    • Bone mineral density (BMD) with DXA.
    • Frequency of fractures.
    • Hearing tests, dental evaluations.
    • For Type III OI → annual echocardiogram (to detect aortic root dilation/valvular issues).
  • Pharmacologic therapy:
    • Bisphosphonates (e.g., pamidronate, alendronate) → shown to increase BMD, decrease fractures, and improve mobility.
    • Monitor for any “mineralization defect” OI types (e.g., Type VI) where bisphosphonates may be less effective or contraindicated.
    • Other treatments under investigation: growth hormone, gene therapy, bone marrow transplant.
  • Prognosis:
    • Type I: Normal life expectancy; mild disease.
    • More severe forms: Shortened lifespan, linked to thoracic deformities and related complications.
    • Skilled orthopedic interventions and bracing may reduce complications and improve quality of life.

Join the
MyEndoConsult Community

We are grateful to the contribution of authors just like you

The MyEndoconsult Team. A group of physicians dedicated to endocrinology and internal medicine education. Learn more about our team

Current Progress
Current Progress
Current Progress
Current Progress
>